AlbertsB., KirschnerM.W., TilghmanS., and VarmusH. (2014). Rescuing US biomedical research from its systemic flaws. Proc. Natl. Acad. Sci. USA, 111, 5773–5777.
2.
BollardC.M., RossigC., CalongeM.J., et al. (2002). Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood, 99, 3179–3187.
3.
BollardC.M., AguilarL., StraathofK.C., et al. (2004). Cytotoxic T lymphocyte therapy for Epstein-Barr virus+Hodgkin's disease. J. Exp. Med., 200, 1623–1633.
4.
BollardC.M., GottschalkS., LeenA.M., et al. (2007). Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood, 110, 2838–2845.
5.
BollardC.M., GottschalkS., TorranoV., et al. (2014). Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J. Clin. Oncol., 32, 798–808.
6.
BrennerM.K., RillD.R., MoenR.C., et al. (1993). Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet, 341, 85–86.
7.
BrentjensR.J., DavilaM.L., RiviereI., et al. (2013). CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med., 5, 177ra38.
8.
CavazzanaM. (2014). Hematopoietic stem cell gene therapy: progress on the clinical front. Hum. Gene Ther., 25, 165–170.
9.
ChiaW.-K., TeoM., WangW.-W., et al. (In press). Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol. Ther., 22, 132–139.
10.
CiceriF., BoniniC., StanghelliniM.T., et al. (2009). Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol., 10, 489–500.
11.
CruzC.R., MicklethwaiteK.P., SavoldoB., et al. (2013). Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood, 122, 2965–2973.
12.
DavilaM.L., RiviereI., WangX., et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med., 6, 224ra25.
13.
Di StasiA., TeyS.K., DottiG., et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med., 365, 1673–1683.
14.
EshharZ., WaksT., GrossG., and SchindlerD.G. (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA, 90, 720–724.
15.
FanL., FreemanK.W., KhanT., et al. (1999). Improved artificial death switches based on caspases and FADD. Hum. Gene Ther., 10, 2273–2285.
16.
GerdemannU., KatariU., ChristinA.S., et al. (2011). Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol. Ther., 19, 2258–2268.
HegdeM., CorderA., ChowK.K., et al. (2013). Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol. Ther., 21, 2087–2101.
19.
HeslopH.E. (2014). Combining drugs and biologics to treat nasopharyngeal cancer. Mol. Ther., 22, 8–9.
20.
HeslopH.E., PriceG.M., PrenticeH.G., et al. (1988). In vitro analysis of the interactions of recombinant IL-2 with regenerating lymphoid and myeloid cells after allogeneic marrow transplantation. J. Immunol., 140, 3461–3466.
21.
HeslopH.E., NgC.Y., LiC., et al. (1996). Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med., 2, 551–555.
22.
HeslopH.E., SlobodK.S., PuleM.A., et al. (2010). Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood, 115, 925–935.
23.
HongengS., KranceR.A., BowmanL.C., et al. (1997). Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet, 350, 767–771.
24.
HwuP., ShaferG.E., TreismanJ., et al. (1993). Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J. Exp. Med., 178, 361–366.
25.
KalosM., LevineB.L., PorterD.L., et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med., 3, 95ra73.
26.
KershawM.H., WestwoodJ.A., ParkerL.L., et al. (2006). A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res., 12, 6106–6115.
27.
KohlerG., and MilsteinC. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495–497.
28.
KungP., GoldsteinG., ReinherzE.L., and SchlossmanS.F. (1979). Monoclonal antibodies defining distinctive human T cell surface antigens. Science, 206, 347–349.
29.
LeenA.M., MyersG.D., SiliU., et al. (2006). Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med., 12, 1160–1166.
30.
LeenA.M., SukumaranS., WatanabeN., et al. (2014). Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol. Ther., 22, 1211–1220.
31.
LinetteG.P., StadtmauerE.A., MausM.V., et al. (2013). Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma. Blood, 122, 863–871.
32.
LouisC.U., StraathofK., BollardC.M., et al. (2009). Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood, 113, 2442–2450.
33.
LouisC.U., StraathofK., BollardC.M., et al. (2010). Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J. Immunother., 33, 983–990.
34.
LouisC.U., SavoldoB., DottiG., et al. (2011). Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood, 118, 6050–6056.
35.
MaherJ., BrentjensR.J., GunsetG., et al. (2002). Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat. Biotechnol., 20, 70–75.
36.
MelcherA., ParatoK., RooneyC.M., and BellJ.C. (2011). Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol. Ther., 19, 1008–1016.
37.
MindenM.D., and MakT.W. (1986). The structure of the T cell antigen receptor genes in normal and malignant T cells. Blood, 68, 327–336.
38.
MorganR.A., ChinnasamyN., Abate-DagaD., et al. (2013). Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother., 36, 133–151.
39.
PapadopoulouA., KranceR.A., AllenC.E., et al. (2014). Systemic inflammatory response syndrome (SIRS) after administration of unmodified T-lymphocytes. Mol. Ther.
40.
PrenticeH.G., JanossyG., Price-JonesL., et al. (1984). Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet, 1, 472–475.
41.
PuleM.A., SavoldoB., MyersG.D., et al. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med., 14, 1264–1270.
42.
RooneyC.M., SmithC.A., NgC.Y., et al. (1995). Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet, 345, 9–13.
43.
RooneyC.M., SmithC.A., NgC.Y., et al. (1998). Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 92, 1549–1555.
44.
RossigC., BollardC.M., NuchternJ.G., et al. (2002). Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood, 99, 2009–2016.
45.
StraathofK.C., BollardC.M., PopatU., et al. (2005a). Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes. Blood, 105, 1898–1904.
46.
StraathofK.C., PuleM.A., YotndaP., et al. (2005b). An inducible caspase 9 safety switch for T-cell therapy. Blood, 105, 4247–4254.
WimperisJ.Z., BrennerM.K., PrenticeH.G., et al. (1986). Transfer of a functioning humoral immune system in transplantation of T lymphocyte depleted bone marrow. Lancet, 1, 339–343.
49.
WimperisJ.Z., GottliebD., DuncombeA.S., et al. (1990). Requirements for the adoptive transfer of antibody responses to a priming antigen in man. J. Immunol., 144, 541–547.
50.
ZhouX., DiS.A., TeyS.K., et al. (2014). Long-term outcome and immune reconstitution after haploidentical stem cell transplant in recipients of allodepleted-T-cells expressing the inducible caspase-9 safety transgene. Blood. [Epub ahead of print]; DOI: http://dx.doi.org/10.1182/blood-2014-01-551671
51.
ZinkernagelR.M., and DohertyP.C. (1974). Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature, 248, 701–702.
